Cautious Optimism for Design Therapeutics: Hold Rating Amid Promising Phase 1 Results and Extended Development Timeline
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Design Therapeutics (DSGN) and Arvinas Holding Company (ARVN)
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Raises Target Price to $5
RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
RBC Capital Remains a Hold on Design Therapeutics (DSGN)
Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress
Design Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Design Therapeutics Analyst Ratings
RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Buy Rating Justified by Design Therapeutics' Innovative Pipeline and Solid Financials
Design Therapeutics Analyst Ratings
Hold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program Updates
Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Design Therapeutics (DSGN) Gets a Hold From Piper Sandler
Hold Rating on Design Therapeutics Amid Mixed Efficacy Data, Strategic Realignment and Financial Uncertainties
Design Therapeutics Analyst Ratings